ReviewMolecular oncology2011
Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?
Review in Molecular oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 56 citations in OpenAlex.
- Remodeling-phase wound-derived protein factors enhance mesenchymal stem cell function and improve diabetic wound healing.Molecular biology reports · 2026Article
- Vascular remodelling and fibrotic changes in the joint capsule during periprosthetic knee infections.Bone & joint research · 2026Article
- Article
- Clinically Relevant and Precisely Printable Live Adipose Tissue-Based Bio-Ink for Volumetric Soft Tissue Reconstruction.Advanced healthcare materials · 2025Article
- CXCR4 Inhibition Induces Tumor Necrosis by Selectively Targeting the Proliferating Blood Vessels in Oral Squamous Cell Carcinoma.Journal of Cancer · 2025Article
- Modeling of chemo-radiotherapy targeting growing vascular tumors: A continuum-level approach.PloS one · 2025Article
- Dexamethasone and OLT1177 Cooperate in the Reduction of Melanoma Growth by Inhibiting STAT3 Functions.Cells · 2023Article
- Development of tissue-engineered tracheal scaffold with refined mechanical properties and vascularisation for tracheal regeneration.Frontiers in bioengineering and biotechnology · 2023Article
- An analysis modality for vascular structures combining tissue-clearing technology and topological data analysis.Nature communications · 2022Article
- Vascularized Lung Cancer Model for Evaluating the Promoted Transport of Anticancer Drugs and Immune Cells in an Engineered Tumor Microenvironment.Advanced healthcare materials · 2022Article
- From protein-protein interactions to immune modulation: Therapeutic prospects of targeting Neuropilin-1 in high-grade glioma.Frontiers in immunology · 2022Review
- Review
- Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma.Journal of experimental & clinical cancer research : CR · 2018Review
- Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?Clinical & translational immunology · 2017Review
- Advances in Age-related Macular Degeneration Understanding and Therapy.US ophthalmic review · 2017Article
- Up-regulation of FGFBP1 signaling contributes to miR-146a-induced angiogenesis in human umbilical vein endothelial cells.Scientific reports · 2016Article
- Article
- Cell density impacts epigenetic regulation of cytokine-induced E-selectin gene expression in vascular endothelium.PloS one · 2014Article
- The involvement of Notch signaling in melanoma vasculogenic mimicry.Clinical and experimental medicine · 2013Article
- Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.Molecular cancer therapeutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis is a pivotal process for growth, invasion and spread of the majority of solid tumors including melanoma. Anti-angiogenic agents have not been systematically tested in patients with advanced melanoma. Clinical efficacy of angiogenesis inhibitors targeting endothelial cells has not been as affirmative as initially hoped and improved clinical outcomes have been observed in combination with chemotherapy or additional drugs for many types of human cancer. However, angiogenesis is not only dependent on endothelial cell invasion and proliferation, it also requires pericyte coverage of vascular sprouts for stabilization and maturation of vascular walls. Recent data suggest that pericytes might be able to confer resistance to anti-vascular endothelial growth factor (VEGF) therapy. This review will focus on the significance of the vascular phenotype but also on the impact of pericyte-mediated vessel maturation for the susceptibility to anti-angiogenic therapy, including malignant melanoma, which we identified as crucial factor regarding therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.